These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

932 related articles for article (PubMed ID: 26308885)

  • 1. Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Ravandi F; O'Brien SM; Cortes JE; Thomas DM; Garris R; Faderl S; Burger JA; Rytting ME; Ferrajoli A; Wierda WG; Verstovsek S; Champlin R; Kebriaei P; McCue DA; Huang X; Jabbour E; Garcia-Manero G; Estrov Z; Kantarjian HM
    Cancer; 2015 Dec; 121(23):4158-64. PubMed ID: 26308885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study.
    Jabbour E; Kantarjian H; Ravandi F; Thomas D; Huang X; Faderl S; Pemmaraju N; Daver N; Garcia-Manero G; Sasaki K; Cortes J; Garris R; Yin CC; Khoury JD; Jorgensen J; Estrov Z; Bohannan Z; Konopleva M; Kadia T; Jain N; DiNardo C; Wierda W; Jeanis V; O'Brien S
    Lancet Oncol; 2015 Nov; 16(15):1547-1555. PubMed ID: 26432046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II trial of hyper CVAD and dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia.
    Benjamini O; Dumlao TL; Kantarjian H; O'Brien S; Garcia-Manero G; Faderl S; Jorgensen J; Luthra R; Garris R; Thomas D; Kebriaei P; Champlin R; Jabbour E; Burger J; Cortes J; Ravandi F
    Am J Hematol; 2014 Mar; 89(3):282-7. PubMed ID: 24779033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy.
    Ravandi F; Jorgensen JL; Thomas DA; O'Brien S; Garris R; Faderl S; Huang X; Wen S; Burger JA; Ferrajoli A; Kebriaei P; Champlin RE; Estrov Z; Challagundla P; Wang SA; Luthra R; Cortes JE; Kantarjian HM
    Blood; 2013 Aug; 122(7):1214-21. PubMed ID: 23836561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study.
    Jabbour E; Short NJ; Ravandi F; Huang X; Daver N; DiNardo CD; Konopleva M; Pemmaraju N; Wierda W; Garcia-Manero G; Sasaki K; Cortes J; Garris R; Khoury JD; Jorgensen J; Jain N; Alvarez J; O'Brien S; Kantarjian H
    Lancet Haematol; 2018 Dec; 5(12):e618-e627. PubMed ID: 30501869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia.
    Ravandi F; O'Brien S; Thomas D; Faderl S; Jones D; Garris R; Dara S; Jorgensen J; Kebriaei P; Champlin R; Borthakur G; Burger J; Ferrajoli A; Garcia-Manero G; Wierda W; Cortes J; Kantarjian H
    Blood; 2010 Sep; 116(12):2070-7. PubMed ID: 20466853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia.
    Kantarjian H; Thomas D; O'Brien S; Cortes J; Giles F; Jeha S; Bueso-Ramos CE; Pierce S; Shan J; Koller C; Beran M; Keating M; Freireich EJ
    Cancer; 2004 Dec; 101(12):2788-801. PubMed ID: 15481055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysis.
    Sasaki K; Jabbour EJ; Ravandi F; Short NJ; Thomas DA; Garcia-Manero G; Daver NG; Kadia TM; Konopleva MY; Jain N; Issa GC; Jeanis V; Moore HG; Garris RS; Pemmaraju N; Cortes JE; O'Brien SM; Kantarjian HM
    Cancer; 2016 Dec; 122(23):3650-3656. PubMed ID: 27479888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term follow-up of imatinib plus combination chemotherapy in patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Lim SN; Joo YD; Lee KH; Kim DY; Lee JH; Lee JH; Chi HS; Yun SC; Lee WS; Lee SM; Park S; Kim I; Sohn SK; Moon JH; Ryoo HM; Bae SH; Hyun MS; Kim MK; Kim HJ; Yang DH; Eom HS; Lee GW; Jung CW; Won JH; Kim H; Lee JH; Shin HJ; Jang DY
    Am J Hematol; 2015 Nov; 90(11):1013-20. PubMed ID: 26228525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Short NJ; Jabbour E; Sasaki K; Patel K; O'Brien SM; Cortes JE; Garris R; Issa GC; Garcia-Manero G; Luthra R; Thomas D; Kantarjian H; Ravandi F
    Blood; 2016 Jul; 128(4):504-7. PubMed ID: 27235138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Daver N; Thomas D; Ravandi F; Cortes J; Garris R; Jabbour E; Garcia-Manero G; Borthakur G; Kadia T; Rytting M; Konopleva M; Kantarjian H; O'Brien S
    Haematologica; 2015 May; 100(5):653-61. PubMed ID: 25682595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Minimal residual disease-based effect and long-term outcome of first-line dasatinib combined with chemotherapy for adult Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Yoon JH; Yhim HY; Kwak JY; Ahn JS; Yang DH; Lee JJ; Kim SJ; Kim JS; Park SJ; Choi CW; Eom HS; Park SK; Choi SY; Kim SH; Kim DW; Lee S
    Ann Oncol; 2016 Jun; 27(6):1081-1088. PubMed ID: 26951627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characteristics of patients with development of large granular lymphocyte expansion among dasatinib-treated patients with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic stem cell transplantation.
    Ito Y; Miyamoto T; Kamimura T; Aoki K; Henzan H; Aoki T; Shiratsuchi M; Kato K; Nagafuji K; Ogawa R; Eto T; Iwasaki H; Akashi K
    Clin Lymphoma Myeloma Leuk; 2015 Mar; 15(3):e47-54. PubMed ID: 25445469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimen.
    Weiser MA; Cabanillas ME; Konopleva M; Thomas DA; Pierce SA; Escalante CP; Kantarjian HM; O'Brien SM
    Cancer; 2004 Mar; 100(6):1179-85. PubMed ID: 15022284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial.
    Jabbour E; Richard-Carpentier G; Sasaki Y; Konopleva M; Patel K; Roberts K; Gu Z; Wang F; Huang X; Sasaki K; Short NJ; Jain N; Ravandi F; Daver NG; Kadia TM; Alvarado Y; DiNardo CD; Issa GC; Pemmaraju N; Garcia-Manero G; Verstovsek S; Wang S; Khoury JD; Jorgensen J; Champlin R; Khouri I; Kebriaei P; Schroeder H; Khouri M; Mullighan CG; Takahashi K; O'Brien SM; Kantarjian H
    Lancet Haematol; 2020 Jul; 7(7):e523-e533. PubMed ID: 32589978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Results of the PETHEMA ALL-96 trial in elderly patients with Philadelphia chromosome-negative acute lymphoblastic leukemia.
    Sancho JM; Ribera JM; Xicoy B; Morgades M; Oriol A; Tormo M; del Potro E; Debén G; Abella E; Bethencourt C; Ortín X; Brunet S; Ortega-Rivas F; Novo A; López R; Hernández-Rivas JM; Sanz MA; Feliu E;
    Eur J Haematol; 2007 Feb; 78(2):102-10. PubMed ID: 17087744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL.
    Rousselot P; Coudé MM; Gokbuget N; Gambacorti Passerini C; Hayette S; Cayuela JM; Huguet F; Leguay T; Chevallier P; Salanoubat C; Bonmati C; Alexis M; Hunault M; Glaisner S; Agape P; Berthou C; Jourdan E; Fernandes J; Sutton L; Banos A; Reman O; Lioure B; Thomas X; Ifrah N; Lafage-Pochitaloff M; Bornand A; Morisset L; Robin V; Pfeifer H; Delannoy A; Ribera J; Bassan R; Delord M; Hoelzer D; Dombret H; Ottmann OG;
    Blood; 2016 Aug; 128(6):774-82. PubMed ID: 27121472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) compared to Hyper-CVAD regimen as salvage chemotherapy in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia.
    Liu L; Jiao W; Zhang Y; Qu Q; Li X; Wu D
    Leuk Res; 2015 Mar; 39(3):323-8. PubMed ID: 25638269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia.
    Faderl S; Kantarjian HM; Thomas DA; Cortes J; Giles F; Pierce S; Albitar M; Estrov Z
    Leuk Lymphoma; 2000 Jan; 36(3-4):263-73. PubMed ID: 10674898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adults with acute lymphoblastic leukemia and translocation (1;19) abnormality have a favorable outcome with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with methotrexate and high-dose cytarabine chemotherapy.
    Garg R; Kantarjian H; Thomas D; Faderl S; Ravandi F; Lovshe D; Pierce S; O'Brien S
    Cancer; 2009 May; 115(10):2147-54. PubMed ID: 19298009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 47.